Amundi - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 56 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Amundi ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,916,506
+21.0%
2,302,000
+21.0%
0.00%0.0%
Q2 2023$1,583,415
-1.3%
1,902,0000.0%0.00%0.0%
Q1 2023$1,603,576
-19.3%
1,902,000
-10.4%
0.00%0.0%
Q4 2022$1,987,659
-19.2%
2,123,000
-26.0%
0.00%0.0%
Q3 2022$2,461,000
+81.0%
2,870,000
+92.4%
0.00%0.0%
Q2 2022$1,360,0001,492,0000.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Wellesley Asset Management 70,776,482$60,420,9114.46%
Lombard Odier Asset Management (Europe) Ltd 41,798,000$35,110,3201.74%
CAMDEN ASSET MANAGEMENT L P /CA 47,123,000$39,937,0731.34%
Penn Mutual Asset Management 1,555,000$1,318,1971.25%
DAVIDSON KEMPNER PARTNERS 66,537,000$56,390,5731.09%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 66,537,000$56,390,5730.96%
ZAZOVE ASSOCIATES LLC 9,443,000$8,0110.73%
SHENKMAN CAPITAL MANAGEMENT INC 8,934,000$7,582,4300.58%
CSS LLC/IL 8,000,000$6,788,2880.45%
READYSTATE ASSET MANAGEMENT LP 5,000,000$4,262,5340.40%
View complete list of HALOZYME THERAPEUTICS INC shareholders